Navigation Links
DATATRAK Launches New Web Site

CLEVELAND, Aug. 26 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the launch of the Company's new web site. Unveiled at the Annual Shareholder Meeting, the interactive web site is a continuation of DATATRAK's singular vision for product and service delivery - DATATRAK ONE(TM).

The web site is available at and delivers content in multiple formats: product videos, informational downloads, RSS feeds, Twitter and email. Visitors to the web site can find out how to empower Clinical Users and Service Providers with the components necessary for efficiently conducting, delivering and managing clinical trials.

"As a key component of the DATATRAK ONE(TM) initiative, the launch of the web site will provide an interactive experience that allows users to explore the breadth of the DATATRAK offerings," said Laurence Birch, DATATRAK's Chairman of the Board.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through an integrated multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Advance Research Associates Joins DATATRAKs CRO Connect Program(TM)
2. DATATRAK Announces New Products and Features at DIA San Diego
3. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
4. DATATRAK International, Inc. Announces First Quarter Results for 2009
5. German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAKs CRO Connect Program(TM)
6. Keypoint Joins DATATRAKs CRO Connect Program(TM)
7. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
8. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
9. DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent
10. DATATRAK Announces Retirement of Chief Executive Officer
11. DATATRAK International, Inc. Receives Notice from NASDAQ
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University ... the Life Sciences Initiative aimed at enhancing Purdue’s life sciences research and graduate ... True” capital campaign. , The investment will result in cohesive efforts across several ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Sir Grout of ... to the local Boston chapter of Ronald McDonald House Charities® (RMHC®). This donation was ... supported Sir Grout of Greater Boston since its inception. , “We believe strongly in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Califia Farms , one ... the release of its limited edition holiday seasonal flavors: Almondmilk Holiday Nog, new ... the unique flavor combinations and delicious taste Califia Farms’ beverages are known for, ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an article published October ... women who successfully lose weight with a bariatric procedure are much less likely to ... article notes that anywhere from 40 to 50 percent of all endometrial cancer cases ...
(Date:10/13/2015)... ... October 13, 2015 , ... Symposium Chairman, Dr. Rod J. ... Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The annual meeting, ... plastic surgeons and cosmetic physicians from around the world. , Key topics at this ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 13, 2015  Kay Elledge, M.D., an established ... College of Obstetrics and Gynecology (FACOG) for the ... the Genuine Self Medical Laser Center where she ... recognition of Breast Cancer Awareness Month , ... MonaLisa Touch treatments initiated in the ...
(Date:10/13/2015)... N.J. , Oct. 13, 2015  ContraVir ... the "Company"), a biopharmaceutical company focused on the ... announced the closing of its previously announced underwritten ... stock and warrants to purchase up to 3,000,000 ... fixed combined price to the public of $3.00. ...
(Date:10/13/2015)... Science Automation (DSA), a system integration and automation engineering firm, ... the United Kingdom (UK) as the ... . The decision to open the new office comes in ... in the medical device industry throughout the UK. ... had tremendous success over the last several years in product ...
Breaking Medicine Technology: